KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Current Deferred Revenue (2016)

Historic Current Deferred Revenue for Gilead Sciences (GILD) over the last 8 years, with Q4 2016 value amounting to $202.0 million.

  • Gilead Sciences' Current Deferred Revenue fell 5409.09% to $202.0 million in Q4 2016 from the same period last year, while for Dec 2016 it was $202.0 million, marking a year-over-year decrease of 5409.09%. This contributed to the annual value of $202.0 million for FY2016, which is 5409.09% down from last year.
  • As of Q4 2016, Gilead Sciences' Current Deferred Revenue stood at $202.0 million, which was down 5409.09% from $361.0 million recorded in Q3 2016.
  • Gilead Sciences' Current Deferred Revenue's 5-year high stood at $529.0 million during Q1 2016, with a 5-year trough of $93.7 million in Q2 2012.
  • Its 5-year average for Current Deferred Revenue is $214.2 million, with a median of $126.8 million in 2013.
  • In the last 5 years, Gilead Sciences' Current Deferred Revenue soared by 29672.48% in 2015 and then crashed by 5409.09% in 2016.
  • Quarter analysis of 5 years shows Gilead Sciences' Current Deferred Revenue stood at $103.2 million in 2012, then rose by 7.6% to $111.0 million in 2013, then grew by 20.72% to $134.0 million in 2014, then skyrocketed by 228.36% to $440.0 million in 2015, then plummeted by 54.09% to $202.0 million in 2016.
  • Its Current Deferred Revenue was $202.0 million in Q4 2016, compared to $361.0 million in Q3 2016 and $345.0 million in Q2 2016.